Feedback / Questions
NPX372 - NextPoint
https://www.businesswire.com/news/home/20260209794023/en/NextPoint-Therapeutics-Announces-Clinical-Entry-of-NPX372-a-First-in-Class-B7-H7Targeted-T-Cell-Engager-to-Treat-Solid-Tumors
Feb 9, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next